Welcome to our dedicated page for TMBR news (Ticker: TMBR), a resource for investors and traders seeking the latest updates and insights on TMBR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TMBR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TMBR's position in the market.
Timber Pharmaceuticals (NYSE American: TMBR) announced that seven abstracts detailing positive clinical data from its Phase 2b CONTROL study of TMB-001 will be presented at the 31st European Academy of Dermatology and Venerology Congress in Milan from September 7-10, 2022. The FDA has designated TMB-001 as a breakthrough therapy for congenital ichthyosis, a rare skin disorder. The studies highlight significant improvements in quality of life and treatment efficacy, showcasing its potential impact on patients suffering from this condition.
Timber Pharmaceuticals has published positive results from its Phase 2b CONTROL study of TMB-001 for treating moderate to severe congenital ichthyosis (CI) in the Journal of the American Academy of Dermatology. The study showed significant efficacy with TMB-001, especially at 0.05% concentration, achieving treatment success rates of 100% in the per-protocol population. Following these promising results, Timber initiated the pivotal Phase 3 ASCEND clinical trial to further evaluate TMB-001 in this patient population. The company is optimistic about the treatment's potential to enhance the quality of life for individuals with CI.
Timber Pharmaceuticals announced the enrollment of the first patients in its Phase 3 ASCEND clinical trial for TMB-001 after receiving Breakthrough Therapy designation from the FDA. This pivotal trial, targeting over 140 patients with moderate to severe Congenital Ichthyosis, aims to demonstrate the efficacy and safety of TMB-001, a topical isotretinoin. The company reported no revenue for Q2 2022, down from $388,819 in Q2 2021, ending with approximately $8.3 million in cash. In August, Timber completed an $8 million financing to support its clinical endeavors.
Timber Pharmaceuticals (TMBR) has completed a public offering of 66,666,667 shares of common stock at $0.12 per share, raising approximately $8.0 million in gross proceeds. The funds will support research and development, including clinical trials, and general corporate purposes. The offering involved warrants with a $0.12 exercise price, expiring in five years. H.C. Wainwright & Co. acted as the placement agent. The offering was registered with the SEC, with effective registration as of August 4, 2022.
Timber Pharmaceuticals, Inc. (TMBR) announced a public offering of 66,666,667 shares of its common stock and associated warrants, priced at $0.12 each. The offering aims to raise approximately $8.0 million for research and development, including clinical trials and working capital. The closing is expected on August 8, 2022. H.C. Wainwright & Co. is the exclusive placement agent. The offering is registered under Form S-1 and follows SEC regulations. This move reflects Timber's commitment to advancing treatments for rare dermatologic diseases.
Timber Pharmaceuticals, Inc. (TMBR) has begun enrolling patients in the pivotal Phase 3 ASCEND clinical trial, targeting over 140 participants with moderate to severe congenital ichthyosis (CI). The trial will assess the efficacy and safety of TMB-001, a topical isotretinoin. The FDA awarded $1.5 million to support earlier trials and granted Breakthrough Therapy and Fast Track designations to TMB-001. The trial, conducted at leading centers in the U.S. and Europe, aims to provide an effective treatment option while minimizing systemic side effects associated with oral isotretinoin.
Timber Pharmaceuticals (TMBR) has received Breakthrough Therapy designation from the FDA for its topical treatment, TMB-001, aimed at congenital ichthyosis (CI). This designation is crucial for expediting the development of therapies for serious conditions. TMB-001 showed significant efficacy in a prior Phase 2b study, demonstrating improvement in CI severity with a favorable safety profile. The company is set to initiate the pivotal Phase 3 ASCEND clinical trial across several countries, expecting to dose the first patients in June 2022.
Timber Pharmaceuticals (TMBR) announced that its lead asset, TMB-001, received Fast Track designation from the FDA, paving the way for a pivotal Phase 3 study anticipated by June 30, 2022. This milestone is crucial for TMB-001's potential as the first FDA-approved therapy for Congenital Ichthyosis, addressing a significant unmet medical need.
The company reported $83,177 in revenue for Q1 2022, up from $40,734 in Q1 2021, attributed to clinical milestone reimbursements from a $1.5 million FDA grant. As of March 31, 2022, Timber had $13.9 million in cash.
Timber Pharmaceuticals (NYSE American: TMBR) announced that the FDA has granted Fast Track designation for TMB-001, a topical treatment for X-linked recessive ichthyosis and autosomal recessive congenital ichthyosis. This designation facilitates more frequent communication with the FDA, potentially accelerating the drug's approval. Timber is set to launch the pivotal Phase 3 ASCEND clinical trial within 60 days, following positive results from its Phase 2b CONTROL study, which showed a significant reduction in ichthyosis severity with TMB-001.
Timber Pharmaceuticals (TMBR) announced a Phase 3 study initiation for TMB-001 in Q2 2022 following positive topline data from its Phase 2b study. The company reported Q4 2021 revenue of $190,005, up from $102,382 in Q4 2020, with total 2021 revenues of $886,532 compared to $453,810 in 2020. Timber ended 2021 with $16.8 million in cash, bolstered by a $17.25 million public offering. However, its financial statements noted a going concern emphasis from auditors, highlighting potential financial uncertainties.